Stockreport
Allogene Therapeutics, Inc. (ALLO) CEO David Chang on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha]
Last allogene therapeutics, inc. earnings: 2/27 04:30 am
Check Earnings Report
Allogene Therapeutics, Inc. (ALLO) CEO David Chang on Q2 2019 Results - Earnings Call Transcript Allogene Therapeutics, Inc. (NASDAQ: ALLO Company Participants Christine Cassiano - Chief Communications Officer David Chang - President, Chief Executive Officer Eric Schmidt - Chief Financial Officer Susie Jun - Chief Development Officer Conference Call Participants Marc Frahm - Cowen and Company Biren Amin - Jefferies Cory Kasimov - JPMorgan Mark Breidenbach - Oppenheimer Dane Leone - Raymond James Raju Prasad - William Blair Tyler Van Buren - Piper Jaffray Ben Burnett - Stifel Tony Butler - Roth Capital Markets Kelsey Goodwin - Guggenheim Operator Good morning, ladies and gentlemen, and thank you for standing by. And welcome to Allogene Therapeutic's Second Quarter 2019 Conference Call. Later we will conduct the question-and-answer session and instructions will follow at that time. Please be aware that today's conference is being recorded. I would now like to turn the conference over to
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | ALLO | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
ALLO alerts
ALLO alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALLO alerts
High impacting Allogene Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ALLO
NEWS
NEWS
- Allogene Therapeutics Announces Participation in Upcoming Investor Conferences[GlobeNewswire]
- Allogene: ALLO-316 Data In RCC Could Lead To Targeting Solid Tumors With CAR T [Seeking Alpha][Seeking Alpha]
- Allogene Therapeutics Reports Third Quarter 2025 Financial Results and Business Update[GlobeNewswire]
- Allogene Therapeutics Announces ALPHA3 Trial-in-Progress Poster Presentation at ASH Annual Meeting[GlobeNewswire]
- Allogene Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update[GlobeNewswire]
- More
ALLO
SEC Filings
SEC Filings
- 11/19/25 - Form 4
- 11/17/25 - Form 144
- 11/13/25 - Form SCHEDULE
- ALLO's page on the SEC website
- More